Novo Nordisk announced it will reduce the U.S. list prices of two insulin products by more than 70% from January of 2026.

The list prices of its insulin drug Fiasp will be reduced by 75%, while the list prices of its Tresiba insulin will be reduced by 72.2%, Novo said in a statement.

As a result, Novo will discontinue Tresiba's unbranded biological versions by the end of this year, it added.